EUCTR2015-005033-53-FI进行中（未招募）1 期
Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled,Parallel-Group, Efficacy and Safety Study Comparing EG-1962 to Standardof Care Oral Nimodipine in Adults with Aneurysmal SubarachnoidHemorrhage - NEWTON 2
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 374
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female between the ages of 18 to 75 years, inclusive
- •2. Ruptured saccular aneurysm confirmed by angiography (CTA, MRA or
- •catheter) and repaired
- •by neurosurgical clipping or endovascular coiling
- •3. Subarachnoid hemorrhage on CT scan (pre-repair) of grade 2-4 on the
- •modified Fisher scale
- •(diffuse [clot present in both hemispheres] thick or thin, or local thick)
- •4. External ventricular drain in place
- •5. WFNS grade 2, 3, or 4 assessed during the Pre-randomization Phase
- •after repair of the
- •aneurysm but prior to randomization
- •6. The subject must be able to receive intraventricular IP within 48
- •hours after the onset of aSAH and within 4 hours after the start time of
- •intraventricular IP suspension in the pharmacy. Onset of aSAH is defined
- •as the time the subject experiences the first symptom of aSAH (e.g.,
- •severe headache or loss of consciousness reported either by the subject
- •or by a witness). If found unconscious, the onset of SAH is defined as
- •the time the subject was last known normal
- •7. Female subjects of child-bearing potential must have a negative
- •pregnancy test (urine or serum) during the Pre-randomization Phase and
- •must agree to use adequate birth control for at least 30 days following
- •the end of the Treatment Period. Male subjects must agree to use
- •adequate birth for at least 30 days after the end of the Treatment Period
- •8. Signed informed consent from the subject or the subject's legal
- •representative after the
- •completion of aneurysm repair but prior to any study-specific procedures
- •being performed
- •9. Able and willing to comply with follow up visit schedule
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range 262
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 112
排除标准
- •1. Major complication during aneurysm repair such as, but not limited to,
- •massive intraoperative hemorrhage, brain swelling, arterial occlusion, or
- •inability to secure the ruptured aneurysm
- •2. Angiographic vasospasm prior to randomization
- •3. Clinical or radiological evidence of a cerebral infarction with
- •neurological deficit
- •4. Increased intracranial (ICP) pressure >30 mm Hg lasting >4 hours
- •anytime during the Prerandomization Phase
- •5. Substantial intraventricular hemorrhage
- •6. Aneurysm repair requiring flow diverting stent or stent-assisted
- •coiling and dual antiplatelet
- •7. Subject is expected to undergo repair of additional aneurysms within
- •90 days in cases where
- •multiple aneurysms were identified during the Pre-randomization
- •PhaseHemodynamically unstable during the Pre-randomization Phase
- •(i.e., systolic blood pressure (SBP) <100 mm Hg, requiring >6 L colloid,
- •or crystalloid fluid resuscitation)
- •9. Cardiopulmonary resuscitation was required during the Prerandomization
- •10. Symptoms or electrocardiogram (ECG) signs of acute myocardial
- •infarction or unstable angina pectoris prior to randomization
- •11. Electrocardiogram evidence and/or physical findings compatible with
- •second or third degree heart block or of cardiac arrhythmia associated
- •with hemodynamic instability
- •12. Echocardiogram, if performed as part of standard of care before
- •randomization, revealing a left ventricular ejection fraction <40%
- •13. Severe or unstable concomitant condition or disease (e.g., known
- •significant neurologic deficit, cancer, hematologic or coronary disease),
- •or chronic condition (e.g., liver disease, kidney disease or psychiatric
- •disorder), that, in the opinion of the investigator, may increase the risk
- •associated with study participation or IP administration, or may
- •interfere with the interpretation of study results
- •14. Subjects who have received an investigational product or
- •participated in another interventional clinical study within 30 days prior
- •to randomization. Subjects participating in a
- •non-interventional study that has no bearing on assessment of EG-1962
- •or enteral nimodipine
- •may be enrolled per guidelines of the local Institutional Review Board
- •(IRB)/Independent
- •Ethics Committee (IEC)
- •15. Known hypersensitivity to nimodipine or other dihydropyridine
- •calcium channel antagonists, poly-D, L-lactide-co-glycolide (PLGA), or
- •hyaluronic acid
研究者
相似试验
进行中（未招募）
1 期
A clinical trial to compare the investigational drug EG-1962 with standard of care oral nimodipine in adults with Subarachnoid Hemorrhage caused by a ruptured aneurysm.Aneurysmal subarachnoid hemorrhage (aSAH)MedDRA version: 19.0Level: LLTClassification code 10072200Term: Asymptomatic subarachnoid hemorrhageSystem Organ Class: 100000004852MedDRA version: 19.0Level: LLTClassification code 10042320Term: Subarachnoid hemorrhageSystem Organ Class: 100000004852EUCTR2015-005033-53-ATEdge Therapeutics, Inc374
进行中（未招募）
1 期
Efficacy and Safety Study of Nipocalimab IV Infusions for Adults With Generalized Myasthenia GravisMyasthenia gravis (MG)EUCTR2020-005732-29-ITJANSSEN CILAG INTERNATIONAL NV105
进行中（未招募）
1 期
Efficacy and Safety Study of Nipocalimab IV Infusions for Adults With Generalized Myasthenia GravisMyasthenia gravis (MG).MedDRA version: 21.1Level: PTClassification code 10028417Term: Myasthenia gravisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-005732-29-DEJanssen-Cilag International N.V.190
进行中（未招募）
1 期
Study to Evaluate the Safety and Effectiveness of XmAb®5871 in Patients with IgG4-Related Disease (INDIGO)IgG4-Related DiseaseMedDRA version: 21.0Level: LLTClassification code 10071581Term: IgG4 related sclerosing diseaseSystem Organ Class: 100000004859EUCTR2017-002214-31-ITXencor INC240
进行中（未招募）
1 期
Efficacy and Safety Study of Nipocalimab IV Infusions for Adults With Generalized Myasthenia GravisMyasthenia gravis (MG).MedDRA version: 21.1Level: PTClassification code 10028417Term: Myasthenia gravisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-005732-29-DKJanssen-Cilag International N.V.190